ong-term study of KRP-108
Phase 3
Completed
- Conditions
- Bronchial asthma
- Registration Number
- JPRN-jRCT2080223577
- Lead Sponsor
- Kyorin Pharmaceutical Co.,LTD
- Brief Summary
o major clinical safety issues were observed when KRP-108 was administered for 24 weeks in Japanese pediatric bronchial asthma patients, and its efficacy was also confirmed.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 53
Inclusion Criteria
Known history of bronchial asthma for > 12 weeks.
Exclusion Criteria
Complication of chronic pulmonary disease without bronchial asthma and diseases affecting respiratory function.
Complication of hypokalemia.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method